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Abstract
The amino acid selenocysteine (Sec) is encoded by UGA codons. Recoding of UGA from stop to Sec requires a Sec insertion
sequence (SECIS) element in the 39 UTR of selenoprotein mRNAs. SECIS binding protein 2 (SBP2) binds the SECIS element
and is essential for Sec incorporation into the nascent peptide. SBP2-like (SBP2L) is a paralogue of SBP2 in vertebrates and is
the only SECIS binding protein in some invertebrates where it likely directs Sec incorporation. However, vertebrate SBP2L
does not promote Sec incorporation in in vitro assays. Here we present a comparative analysis of SBP2 and SBP2L SECIS
binding properties and demonstrate that its inability to promote Sec incorporation is not due to lower SECIS affinity but
likely due to lack of a SECIS dependent domain association that is found in SBP2. Interestingly, however, we find that an
invertebrate version of SBP2L is fully competent for Sec incorporation in vitro. Additionally, we present the first evidence
that SBP2L interacts with selenoprotein mRNAs in mammalian cells, thereby implying a role in selenoprotein expression.
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Introduction
Selenoproteins are unique in that they contain the amino acid
selenocysteine (Sec). Commonly referred to as the 21st amino acid,
Sec is encoded by UGA codons which typically specify translation
termination. In order to recode UGA from stop to Sec,
selenoprotein mRNAs contain a Sec insertion sequence (SECIS)
element in their 39 UTRs which is recognized by SECIS binding
protein 2 (SBP2). Although mechanistic detail is lacking, the
concerted action of SECIS-bound SBP2 and the Sec specific
translation elongation factor (eEFSec) is essential for recoding
UGA from stop to Sec and delivering Sec-tRNA
Sec to the
ribosomal A-site [1–3].
Eukaryotic SECIS elements are stable stem-loop structures that
belong to the kink-turn family of RNAs [2,4]. They are comprised
of two helices separated by an internal loop of 4–18 nucleotides
[5]. The base of helix 2 contains 4 non-Watson-Crick base pairs
including the tandem G.A/A.G ‘‘quartet’’ that with a 59 RU forms
the conserved SECIS core motif (AUGA) and is essential Sec
incorporation [4,6–9]. SECIS elements also have an apical motif
comprised of three unpaired adenosines or cytidines that are
required for Sec incorporation [5,10,11]. Additionally, there are
two forms of SECIS elements: Form 1 SECIS elements have a
large apical loop while Form 2 SECIS elements have a smaller
apical loop that is separated from helix 2 by a bulge and third
helix. No functional differences have been described for either
SECIS form, but a recent survey found that Form 2 is more
prevalent [5].
SECIS elements direct Sec incorporation upon recognition of
the core motif by SBP2. Structure-function analyses have divided
SBP2 into an N-terminal domain that is dispensable for Sec
incorporation, a central Sec incorporation domain (SID), and a C-
terminal RNA binding domain (RBD) that contains an L7Ae RNA
binding motif [12]. The C-terminal half of SBP2 (CT-SBP2; rat
a.a. 399–846, human a.a. 408–854) is sufficient to promote Sec
incorporation. Both the SID and RBD are required for Sec
incorporation activity, but a non-conserved region between the
SID and RBD is dispensable as are residues downstream of the
RBD (C-terminal of rat a.a. 777; human a.a. 783) [12,13].
Additionally, residues in the C-terminus of the SID have been
implicated in differential SECIS affinity and mediate stable
SECIS-dependent interaction of the SID and RBD that appears
necessary for Sec incorporation [13–15].
A homologue of SBP2, termed SBP2-like (SBP2L), was
identified in BLAST searches when SBP2 was first cloned [16],
and a subsequent survey of eukaryotic SECIS binding proteins
(SBPs) found that SBP2 and SBP2L are paralogues in vertebrates
while SBP2L is the sole SBP in some invertebrates including sea
urchins, sea squirts, and an annelid worm in the genus Capitella
[17]. Since invertebrate SBP2L is the only SBP in these organisms
it likely fulfills the known functions of mammalian SBP2. Although
selenoproteins have not been detected by metabolic labeling with
75Se in these organisms, they have been detected by in silico
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including the SECIS was cloned from a sea squirt, Halocynthia
roretzi, and its enzymatic activity in transfected mammalian cells
depended on the Sec codon [20], providing indirect support for
invertebrate SBP2L as a Sec incorporation factor. This notion
stands in contrast to the observation that a C-terminal fragment of
human SBP2L (CT-SBP2L; a.a. 467–1101) that is homologous to
CT-SBP2 cannot direct Sec incorporation in vitro [12,17].
Although SBP2 and SBP2L are similar, there are several defining
features that clearly distinguish the proteins. These include five
sequence motifs surrounding the SID and RBD as well as a poly-
glutamate motif C-terminal to the RBD that are exclusively found
in SBP2L [17]. Thus, with the exception of a short N-terminal
motif, conservation between SBP2 and SBP2L is limited to the
SID and RBD [17,21]. The conservation between vertebrate
SBP2L, invertebrate SBP2L, and mammalian SBP2, point toward
a role for SBP2L in the post-transcriptional regulation of
selenoprotein expression and it has been postulated that SBP2L
may direct selenocysteine incorporation for a subset of the
vertebrate selenoproteome [17].
In this report we used in vitro RNA binding assays to determine
the affinities of human SBP2 and SBP2L for the 26 known human
SECIS elements. Additionally, we found that the SID and RBD of
SBP2L, unlike those of SBP2, do not interact in a SECIS
dependent manner thereby explaining its inability to promote Sec
incorporation in vitro. Interestingly, SBP2L from the worm Capitella
teleta is able to promote robust Sec incorporation, confirming the
role of SBP2L as the Sec incorporation factor in this organism.
Lastly, we found that selenoprotein mRNAs co-immunoprecipitate
with both SBP2 and SBP2L suggesting the existence of at least two
selenoprotein mRNP populations and implicating SBP2L in the
post-transcriptional regulation of selenoprotein expression.
Results
Capitella SBP2L promotes Sec incorporation
We have previously demonstrated that mammalian SBP2L lacks
Sec incorporation activity in a rabbit reticulocyte lysate in vitro
translation assay [12,17]. However, since some invertebrate
organisms possess only SBP2L, we decided to test the ability of
one such SBP2L to promote Sec incorporation in an in vitro
translation assay. Based on genomic and expressed sequence
tagged sequences, we synthesized the portion of Capitella SBP2L
that corresponds to the active C-terminal fragment of mammalian
SBP2 (Figure S1). This protein was in vitro translated in rabbit
reticulocyte lysate, quantitated, and 5 fmol was added to a
separate in vitro translation reaction programmed with a luciferase
reporter mRNA that harbored various SECIS elements: wild-type
or mutant human glutathione peroxidase 4 (GPX4, a Form 1
SECIS element), human selenoprotein V (SelV, a Form 2 SECIS
element) and Capitella selenoprotein T (SelT, Form 2; diagrammed
in Figure 1A). The same experiment was performed with human
CT-SBP2 as a positive control. As shown in Figure 1B, Capitella
CT-SBP2L is able to support Sec incorporation from all three
SECIS elements to varying extents, but no Sec incorporation was
detected from a GPX4 SECIS element that harbored an
AUGARAUCC mutation. It is interesting to note that the
Capitella SelT SECIS element, which has not previously been
tested, appears to permit Sec incorporation with approximately a
three-fold higher efficiency, but both CT-SBP2 and Capitella CT-
SBP2L enhance Capitella SelT based Sec incorporation to the same
extent (Figure 1C). It is also notable that Capitella CT-SBP2L
shows an impaired ability to stimulate GPX4-based Sec incorpo-
ration. Interestingly, both the human SelV and Capitella SelT
SECIS elements are of the form 2 variety, while human GPX4 is
form 1. In addition, since no form 1 SECIS elements have been
identified in invertebrates, it is possible that Capitella CT-SBP2L is
inherently less active with form 1 SECIS elements. Overall these
results clearly establish that Capitella SBP2L is able to promote Sec
incorporation in a SECIS-core dependent fashion to approxi-
mately the same extent as human CT-SBP2. While these results do
not directly shed light on the function of mammalian SBP2L, it is
clear that possessing the conserved SBP2L features is not sufficient
to prevent Sec incorporation activity.
Recombinant CT-SBP2L does not promote Sec
incorporation
Previous studies showed that limiting amounts of in vitro
translated human CT-SBP2L (Figure 2A; a.a. 467–1101) could
not promote Sec incorporation when rabbit reticulocyte lysate was
programmed with mRNA encoding the selenoprotein GPX4 or a
luciferase reporter mRNA containing an in-frame UGA codon
and rat GPX4 SECIS element in the 39 UTR [12,17]. In those
cases, the amount of SBP2L was limited by in vitro translation, so in
Figure 1. Capitella CT-SBP2L is able to promote Sec incorpora-
tion. (A) Diagram of the luciferase Sec incorporation reporter construct.
(B) 5 fmol of in vitro translated CT-SBP2 (blue bars) or Capitella CT-SBP2L
(red bars) were added to a rabbit reticulocyte lysate assay programmed
with a luciferase reporter construct containing a Sec codon at position
258 and the SECIS element indicated. The data is reported as the mean
6 standard deviation of three experiments (except for the mutant GPX4
SECIS element, which was only tested once). (C) The data from (B) was
replotted to show the fold enhancement of Sec incorporation upon the
addition of either CT-SBP2 (blue bars) or Capitella CT-SBP2L (red bars).
doi:10.1371/journal.pone.0035581.g001
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tested the ability of recombinant CT-SBP2L to promote Sec
incorporation in a luciferase reporter mRNA. The reporter
mRNA was translated in rabbit reticulocyte lysate in the presence
of [
35S]-Met and 0–160 nM recombinant human CT-SBP2 or
CT-SBP2L and aliquots of the translation reactions were analyzed
by SDS-PAGE and phosphorimaging. As expected, only the
translation product resulting from termination at the Sec codon
was visible in the absence of added protein (Figure 2B, lane 1;
Term). The addition of recombinant human CT-SBP2 resulted in
the production of full-length luciferase due to Sec incorporation at
the UGA codon (lanes 2–6; FL). Consistent with previous results,
CT-SBP2L did not promote Sec incorporation at any of the
concentrations tested (lanes 7–11). In addition, it is noteworthy
that increasing concentrations of CT-SBP2L did not alter the
amount of termination product suggesting that SBP2L neither
destabilizes selenoprotein mRNAs nor inhibits translation initia-
tion (compare termination product in lane 1 to lanes 7–11). These
results further support the idea that mammalian SBP2L does not
directly participate in the Sec incorporation reaction in a manner
analogous to that of SBP2.
SBP2L has lower affinity for SECIS elements than SBP2
We have previously shown that SBP2L is a bona fide sequence-
specific SECIS binding protein albeit with a lower apparent
binding affinity for the rat GPX4 SECIS element [12]. A
subsequent analysis of SBP2/SBP2L chimeric proteins led us to
hypothesize that vertebrate SBP2L may promote Sec incorpora-
tion for a subset of the selenoproteome [17]. Thus, we set out to
determine the affinities of human SBP2 and SBP2L for all known
human SECIS elements with two questions in mind: 1) Does
SBP2L have a higher affinity than SBP2 for any SECIS elements
and 2) If so, can SBP2L promote Sec incorporation using a SECIS
element for which it has higher affinity than SBP2? We used an
electrophoretic mobility shift assay (EMSA) to determine the
apparent dissociation constant (Kd) of each human SECIS element
for recombinant CT-SBP2 and CT-SBP2L. The concentration of
recombinant protein required to shift 50% of the labelled SECIS
RNA was considered to be the apparent Kd. Several representative
EMSAs used for determining Kd values are shown in Figure 3.
The dissociation constants of all the SECIS elements with CT-
SBP2 and CT-SBP2L are listed in Table 1. We found that CT-
SBP2L and CT-SBP2 bound all SECIS elements. CT-SBP2L has
the highest affinity for the SelV SECIS (Kd=12.4 nM) and the
lowest affinity for the GPX6 SECIS (Kd=313.2 nM) while CT-
SBP2 has the highest affinity for selenoprotein P SECIS 2
(Kd=1.6 nM) and the lowest affinity for the GPX6 SECIS
(Kd=149.8 nM). Overall CT-SBP2L has a lower affinity for
SECIS elements with an average Kd of 81.7 nM while that of CT-
SBP2 is 13.5 nM (Figure 4A). Additionally CT-SBP2L was unable
Figure 2. CT-SBP2L does not promote Sec incorporation. (A) Domain architecture of human SBP2 and SBP2L. The conserved Sec incorporation
domains (SID) and RNA binding domains (RBD) are indicated. The C-terminal (CT2) portions of the proteins used through this study are underlined.
(B) A representative gel showing [
35S]-Met labeled translation products of the Sec incorporation reporter mRNA in the presence of the indicated
recombinant proteins. Full-length (FL) product is the result of Sec incorporation while the termination product (Term) results from translation
termination at the in-frame UGA/Sec codon.
doi:10.1371/journal.pone.0035581.g002
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Visualizing the affinities of SECIS elements for CT-SBP2L as a
function of affinity for CT-SBP2 showed that there is no
relationship between SECIS element binding affinities for SBP2
and SBP2L (Figure 4B). Since SECIS elements exist in two major
classes, Form 1 with a single terminal loop and Form 2 with a
minihelix separating a bulge from the apical loop, we also
examined whether or not there was a relationship between SECIS
form and SBP affinity. The average Kd values of CT-SBP2 and
CT-SBP2L for Form 1 SECIS elements were lower than that for
all SECIS elements (6.8 nM and 69.7 nM, respectively) while that
for Form 2 SECIS elements were higher than the overall average
(17.6 and 93.6 nM, respectively; Figure 4C). We found no
relationship between CT-SBP2 and CT-SBP2L affinities for Form
1 or Form 2 SECIS elements (data not shown). These results
demonstrate that both SBP2 and SBP2L bind all known SECIS
elements with a wide range of affinities but do not yield any
distinction between Form 1 and 2 SECIS elements. The
overlapping ranges of SECIS binding affinities for CT-SBP2 and
CT-SBP2L suggest that the inability of CT-SBP2L to promote Sec
incorporation is not due to poor SECIS binding. This was
experimentally verified by testing the ability of CT-SBP2L to
promote Sec incorporation with the human SelV SECIS element.
To that end, we sub-cloned the human SelV SECIS element into
the luciferase Sec incorporation reporter. Figure 4D shows that
even across a broad range of CT-SBP2L protein (10–160 nM)
concentrations, no Sec incorporation is detectable. The same
range of CT-SBP2 showed saturating Sec incorporation activity at
approximately 40 nM.
In order to verify that the SBP2L-SECIS interaction is driven by
the conserved L7Ae motif, we tested the SECIS binding activity of
mutated CT-SBP2L. The L7Ae motif in the SBP2 RNA binding
domain recognizes the SECIS core and mutating a universally
conserved glycine within the L7Ae motif to arginine disrupts
SBP2-SECIS interactions [12]. Since SBP2L-SECIS interactions
are also SECIS core-dependent [12,17], we reasoned that
mutating the conserved glycine in the SBP2L L7Ae motif (G721)
to arginine would inhibit SECIS binding. Indeed, the G721R
mutation in CT-SBP2L inhibited binding to both the SelV and
thioredoxin reductase 1 (TR1) SECIS elements (Figure 5A). This
suggests that SBP2 and SBP2L have an overlapping, if not the
same, binding site on the SECIS element. We further tested the
impairment of SECIS binding activity in the G721R mutation in
competitive SECIS binding assays using UV crosslinking. As
shown in Figure 5B, the signal generated from UV cross-linking
radiolabeled SECIS element to CT-SBP2 decreases with increas-
ing concentrations of wild type but not mutant CT-SBP2L with a
concentration of 71 nM at 50% inhibition (IC50). Note that the
residual UV crosslinked signal observed in the G721R CT-SBP2L
mutant is not unexpected, as this assay permits the observation of
non-specific and transient RNA protein interactions. Interestingly,
the same competitive assay when performed in an EMSA showed
that SBP2 and SBP2L form separate complexes without a
supershift indicating that they do not simultaneously interact with
the same SECIS element (Figure 5C). It follows from these results
that CT-SBP2L should inhibit Sec incorporation in vitro when
present at concentrations high enough to compete for SBP2
binding to the SECIS element. Indeed, Figure 5D shows that wild-
type but not the G721R mutant CT-SBP2L is able to reduce Sec
incorporation with an IC50 of ,160 nM. The fact that this IC50
is more than twice that observed in the UV crosslinking
experiment (Figure 5B), suggests that the SBP2/SECIS interaction
may be stabilized by other factors in the rabbit reticulocyte lysate.
Together these data indicate that both SBP2L and SBP2 interact
with a SECIS element by a similar mechanism, suggesting that
SBP2L cannot support Sec incorporation because of a defect
downstream of SECIS binding.
SBP2L SID-RBD interactions differ from those in SBP2 and
provide a mechanistic explanation for lack of Sec
incorporation
We previously reported that the SBP2 Sec incorporation and
RNA binding domains (SID and RBD, respectively) interact in a
SECIS dependent manner and are fully competent for Sec
incorporation when expressed as separate proteins [14]. Since
recombinant and in vitro translated SBP2L do not promote Sec
incorporation, we set out to determine whether or not a lack of
domain interaction between the SBP2L SID and RBD may
explain the lack of Sec incorporation activity. To test this we
subcloned SBP2L fragments that contain the SID (a.a. 467–647)
and RBD (a.a. 648–1101) and expressed them as N-terminally
His-Xpress and His-FLAG tagged recombinant proteins, respec-
tively. SID-RBD interactions were assayed by immunoprecipitat-
ing the RBD with a-FLAG agarose in the presence or absence of
wild-type or mutant rat GPX4 SECIS elements. We used N-
terminally His-Xpress tagged rat SBP2 SID (a.a. 399–585) and
FLAG tagged RBD (a.a. 586–846) as a positive control. As shown
in Figures 6A and B neither the SBP2 nor SBP2L SID
immunoprecipitates in the absence of RBD and SECIS (lanes 1
and 6). The SID from both proteins also does not pellet when
incubated with RBD alone (Figures 6A and B; lanes 2 and 7). As
expected, the SBP2 SID was pulled down by the SBP2 RBD in the
presence of wild-type but not the DAUGA SECIS mutant
(Figure 6A; lanes 3 and 4). The SBP2 SID also interacted with
the SBP2 RBD in the presence of the apical loop mutant SECIS
element (Figure 6A; lane 5). Surprisingly, the SBP2L SID showed
dramatically reduced co-immunoprecipitation with the SBP2L
RBD in the presence of wild-type or mutant SECIS elements
(Figure 6B; lanes 8–10). Western blot analysis of the supernatant
Figure 3. SBP2L is a universal SECIS binding protein. Represen-
tative EMSA gels of CT-SBP2 and CT-SBP2L with the human GPX2 (A),
SelW (B), SelH (C), and SelV (D) SECIS elements.
doi:10.1371/journal.pone.0035581.g003
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eliminating protein degradation as a reason for lack of SID
pelleting (Figure 6B, lanes 6–10, middle panel). The lack of SBP2L
SID pelleting cannot be explained by RNA degradation as all
SECIS RNAs were recovered from the supernatant after
immunoprecipitation (Figure 6B, bottom panel). We repeated this
assay with the human GPX4 and SelV SECIS elements and found
that neither SECIS could promote stable association of the SBP2L
SID and RBD (Figure S2).
These results suggest that SBP2L may not participate in Sec
incorporation due to a lack of stable SID-RBD interactions and
raise the question of whether or not it would be able to promote
Sec incorporation if such a stable interaction could be induced. To
this end we considered differences between CT-SBP2 and CT-
SBP2L. The region between the SID and RBD is conserved in
SBP2L but not in SBP2 and SBP2L has a conserved C-terminal
extension relative to SBP2 that contains a Glu-rich motif [17].
Furthermore, deletion of the region between the SID and RBD
did not affect the ability of SBP2 to participate in Sec
incorporation [13]. We set out to determine if deletion of the
inter-domain region (D602–663) or deletion of the C-terminal
extension (D829–1101) could activate CT-SBP2L. Neither mutant,
alone or together, conferred Sec incorporation activity to CT-
SBP2L, suggesting that these regions do not contain inhibitory
domains (Figure S3). These results are consistent with our finding
that Capitella CT-SBP2L, which also contains these domains, is
fully active for Sec incorporation in vitro and they reinforce the idea
that mammalian SBP2L is not directly involved in Sec
incorporation.
Mammalian cells have two distinct selenoprotein mRNP
populations
To date all attempts to determine SBP2L function have relied
on in vitro assays which may not reproduce conditions required for
proper function. Therefore we hypothesized that altering SBP2L
expression in mammalian cells could affect selenoprotein expres-
sion. First, we transiently transfected HEK293 cells with vectors
expressing wild-type or G721R CT-SBP2L followed by metabolic
labeling of selenoproteins with
75Se. Over-expression of CT-
SBP2L did not alter endogenous selenoprotein expression
(Figure 7A and B), and we were unable to express detectable
full-length SBP2L (data not shown). Additionally, we attempted
SBP2L knockdown using shRNAs, but we achieved only modest
reduction of SBP2L in HEK293 cells stably transfected with an
shRNA vector targeting SBP2L. Metabolic labeling of these cells
with
75Se showed that SBP2L knockdown did not affect
selenoprotein expression (data not shown). Despite these data
there remains a strong evolutionary argument that SBP2L is a
factor that post-transcriptionally regulates selenoprotein expres-
sion. Therefore, selenoprotein mRNAs might be associated with
SBP2L in vivo. We tested this hypothesis by co-immunoprecipita-
tion from U87MG human glioblastoma cells as this cell line has
higher expression levels of SBP2L compared to more commonly
used cells lines (i.e. HeLa, HEK293) according to microarray data
from the human gene atlas available through BioGPS [22,23].
Prior to determining whether or not selenoprotein mRNAs co-IP
with SBP2L we verified that our antibody can IP SBP2L (Figure
S4). We cultured U87MG cells and immunoprecipitated SBP2L
from cytoplasmic extracts. RNA was extracted from half of the
pellet and the other half analyzed for protein content by mass
spectrometry. Proteomic analysis detected SBP2L but not SBP2
(data not shown), verifying the lack of cross-reactivity between the
anti-SBP2L antibody and human SBP2. This is further supported
by lack of SBP2 immunoreactivity on western blots of SBP2L
immunoprecipitations (data not shown). We performed RT-PCR
on the RNA samples and found that mRNA of the selenoproteins
GPX4 and TR1 were enriched in the a-SBP2L sample compared
to the pre-immune sample while b-actin mRNA non-specifically
immunoprecipitated with both the immune and pre-immune
antibodies (Figure 8A; lanes 4 and 6). Additionally, we
immunoprecipitated SBP2 or SBP2L from PC3 human prostate
cancer cell cytoplasmic extract. RT-PCR analysis of these
immunoprecipitations showed specific association of selenoprotein
mRNAs (GPX1 and GPX4) with SBP2 (Figure 8B; compare lanes
4 and 6) and SBP2L (Figure 8B; compares lanes 8 and 10). These
results implicate SBP2L in the post-transcriptional regulation of
selenoprotein expression and demonstrate that mammalian cells
have at least two selenoprotein mRNP populations.
Discussion
In this report we investigated the potential role of SBP2L in
regulating selenoprotein expression. We initially hypothesized that
SBP2L might direct Sec incorporation for a subset of the
selenoproteome and that this could be uncovered by analyzing
the SECIS binding properties of SBP2L and comparing them to
Table 1. Apparent dissociation constants of CT-SBP2 and CT-
SBP2L for all human SECIS elements.
Apparent Kd (nM)*
SECIS CT-SBP2 CT-SBP2L Form
GPX1 6.360.1 112.1611 1
GPX2 10.962.3 135.0626.1 1
GPX3 25.0613.8 135.0626.2 2
GPX4 13.262.8 58.262.9 1
GPX6 149.8639.5 313.2631.8 2
SEP15 5.060.4 52.9612.9 2
SelH 4.760.6 102.4611.8 1
SelI 12.261.7 59.265.5 2
SelK 3.662.0 32.964.6 2
SelM 3.060.1 23.460.1 2
SelN 10.560.1 89.063.5 1
SelO 7.060.7 58.769.3 2
SelP SECIS 1 3.460.1 59.265.3 2
SelP SECIS 2 1.660.0 27.663.6 1
SelR 9.760.2 195.8621.3 2
SelS 25.966.7 93.064.4 2
SelT 4.060.2 102.362.0 1
SelV 6.760.2 12.460.4 1
SelW 4.060.2 87.768.4 2
SPS2 7.560.6 129.2619.8 1
DIO1 2.760.9 19.964.8 1
DIO2 6.863.5 71.3633.7 2
DIO3 5.462.2 55.7619.6 2
TR1 5.860.7 20.660.5 2
TR2 11.660.9 54.462.0 2
TR3 4.260.2 114.7619.8 2
*Mean 6 standard deviation; n=2.
doi:10.1371/journal.pone.0035581.t001
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participation in Sec incorporation but showed an association of
selenoprotein mRNAs with SBP2L in cell extracts supporting a
role for SBP2L in the post-transcriptional regulation of seleno-
protein expression. In addition, the fact that the evolutionarily
more ‘‘ancient’’ form of SBP2L from Capitella is fully active for Sec
incorporation in vitro supports the conclusion that mammalian
SBP2L is not directly involved in the Sec incorporation reaction,
but the possibility that mammalian SBP2L plays a role under
specific conditions cannot be ruled out.
SECIS binding: SBP2 versus SBP2L
SBP2 and SBP2L comprise the SECIS binding protein family
that possess the characteristic Sec incorporation domain and an
RNA binding domain containing an L7Ae RNA binding motif.
This study and previous works demonstrated that the interaction
of SBP2 and SBP2L with SECIS elements is dependent on the
SECIS core motif, suggesting that these proteins have the same
binding site on the SECIS element. This is supported by several
observations: 1) mutation of a universally conserved glycine within
the L7Ae motif disrupts SECIS binding by SBP2 and SBP2L (this
study and [6,12]), 2) SBP2 residues predicted to contact SECIS
RNA [6] are conserved between SBP2 and SBP2L [17], and 3)
SBP2L competes with SBP2 for SECIS binding in vitro (Figure 4).
Extending this competitive binding to the intracellular milieu
suggests that there is one SBP per SECIS element at a given time
and silver stained SDS-PAGE gels of eluates from large-scale
immunoprecipitations suggest that SBP2 and SBP2L are not part
of the same complex (Donovan and Copeland, unpublished
observation).
Although they share the same binding site, the differing affinities
for SECIS elements displayed by SBP2 and SBP2L suggest their
binding mechanisms may be different. An IILKE motif and
nearby residues in the C-terminus of the SBP2 SID are known
modulators of SECIS affinity [13–15]. These residues are well
conserved between SBP2 and SBP2L suggesting a minimal role in
explaining the observed differences between SBP2 and SBP2L
SECIS affinities. Gagnon et al. recently analyzed signature
residues in L7Ae and its eukaryotic homologue, 15.5 kDa protein,
for their contributions to K-turn and K-loop RNA binding [24].
Archaeal L7Ae can recognize K-turn and K-loop motifs in
archaeal box C/D and box H/ACA while 15.5 kDa protein is
limited to binding K-turn motifs in small nucleolar RNAs. The
authors identified a single residue upstream of the conserved
glycine and a downstream tetrapeptide motif that are determinants
of RNA ligand recognition [24]. The equivalent residues are R672
and KAVP
740–743 in human SBP2 and R717 and KLVP
785–788 in
human SBP2L. Structure modeling using the human 15.5 kDa
protein bound to its target U4 RNA as a model (PDB coordinates
1E7K), suggests these signature motifs in SBP2 and SBP2L would
Figure 4. Summary of SECIS binding data. (A) The mean apparent dissociation constants (Kd) for CT-SBP2 and CT-SBP2L obtained from the
values reported in Table 1. (B) Scatterplot of CT-SBP2L SECIS dissociation constants as a function of CT-SBP2 SECIS dissociation constants. (C) Mean
dissociation constants of CT-SBP2 and CT-SBP2L for Form 1 and Form 2 SECIS elements. (D) Total luciferase activity from a luciferase Sec incorporation
reporter construct containing the human SelV SECIS element. A range of recombinant CT-SBP2 or CT-SBP2L (10–160 nM) was added as indicated.
doi:10.1371/journal.pone.0035581.g004
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sized internal loop of the SECIS element (Donovan and Copeland,
unpublished observation). Thus it is tempting to speculate that the
bulkier leucine residue in the SBP2L L7Ae RNA binding motif
could contribute to the observed differences in SBP2 and SBP2L
SECIS binding affinities.
A connection between SECIS affinity and function?
We initially hypothesized that SBP2L might promote Sec
incorporation in the presence of SECIS elements for which it has
high affinity. However, Latre `che et al. recently tested the UGA
recoding ability of all human SECIS elements and reported that
there was no relationship between SBP2-SECIS affinity and
recoding efficiency based on dissociation constants of SBP2 for the
SelR and GPX3 SECIS elements which were used as represen-
tative strong and weak SECIS elements, respectively [25]. We
obtained similar dissociation constants for SBP2-SelR and SBP2-
GPX3 complexes and comparison of all SECIS-SBP2 affinities
with the recoding efficiencies reported by Latre `che and colleagues
reiterates the lack of correlation between SBP2 affinity and UGA
recoding efficiency: DIO2, SelV, and SelO were classed as strong,
moderate, and weak SECIS elements, respectively [25], but have
similar affinities for SBP2 (Table 1). Similarly, there is no apparent
relationship to SBP2L-SECIS affinity and recoding efficiency: SelP
SECIS 1 and SelO are strong and weak SECIS elements,
respectively, but have approximately the same affinity for SBP2L
(,60 nM) while another strong SECIS element, SelR, has the
second lowest affinity for SBP2L (195 nM). Together these
observations suggest that competitive SECIS binding based solely
on affinity derived from in vitro experiments does not affect
selenoprotein expression. This is also supported by CT-SBP2L
overexpression data (discussed below).
SBP2L as a post-transcriptional regulator
We attempted to address the function of SBP2L in human cell
lines by manipulating expression levels of SBP2L in HEK293 cells.
Our attempt to over-express full length SBP2L by transient
transfection was unsuccessful and was not rectified by cloning an
intron back into the SBP2L cDNA despite having similar
transfection efficiency as CT-SBP2L (data not shown). Transient
over-expression of CT-SBP2L did not affect selenoprotein
expression suggesting that SBP2L does not inhibit selenoprotein
expression by competing for SECIS elements with SBP2. This
phenomenon has been observed for an unrelated RNA binding
Figure 5. SBP2 and SBP2L compete for SECIS binding in vitro. (A) EMSA of 20 nM wild-type (WT) or mutant (G721R) CT-SBP2L with the
indicated SECIS elements. (B) Top: UV Cross-linking (X-link) of CT-SBP2 and CT-SBP2L. Bottom: Quantitation of CT-SBP2 signal in the presence of
increasing concentrations of CT-SBP2L. (C) EMSA of the SelV SECIS element with CT-SBP2 in the presence of increasing amounts of CT-SBP2L. (D) Sec
incorporation activity in the presence of 8 nM CT-SBP2 plus 160 nM wild-type or G721R mutant CT-SBP2L. Luciferase activity from 1 nM luciferase
mRNA harboring the SelV SECIS element is normalized to a reaction containing no CT-SBP2L (left bar).
doi:10.1371/journal.pone.0035581.g005
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competing with SBP2 for SECIS binding [26]. Since over-
expression of CT-SBP2L did not reduce selenoprotein expression,
it also suggests that it does not increase turnover rates of
selenoprotein mRNAs. SBP2L knockdown also did not affect
selenoprotein expression. However, this lack of an effect could be
explained by insufficient knockdown or potentially redundant
functions in SBP2 masking any effect.
We also demonstrated for the first time that selenoprotein
mRNAs co-immunoprecipitate with SBP2L from mammalian
cytoplasmic extracts thereby implicating it as a post-transcriptional
regulator of selenoprotein expression and establishing two distinct
selenoprotein mRNPs that can be defined by their respective
Figure 6. The SBP2L SID and RBD do not stably interact. (A) 6xHis-Xpress tagged rat SBP2 SID was incubated with FLAG tagged rat SBP2 RBD
and wild-type (WT), core deleted (DAUGA), or loop mutant (TTT) rat GPX4 SECIS as indicated and complexes were immunoprecipitated (IP) with a-
FLAG agarose. Top western blot: 50% pellet; middle western blot: 7.5% supernatant; bottom panel: RNA extracted from 50% of the supernatant was
resolved on an agarose gel. (B) Same as in panel A but 6xHis-Xpress tagged SBP2L SID was incubated with 6xHis-FLAG tagged SBP2L RBD.
doi:10.1371/journal.pone.0035581.g006
Figure 7. Overexpressing CT-SBP2L does not alter selenoprotein expression. HEK293 cells were transiently transfected with empty vector,
wild-type (WT), or G721R CT-SBP2L expression vectors and labeled for 24 h with
75Se. (A) Equal amounts of cell lysates were analyzed by western
blotting for SBP2L and b-actin. (B) Equal amounts of cell lysates were fractionated by SDS-PAGE. The gel was stained (left) to visualize total protein
and
75Se labeled proteins were detected by phosporimaging (right).
doi:10.1371/journal.pone.0035581.g007
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vertebrate SBP2L relative to SBP2 and its conservation with
invertebrate SBP2L [17], suggests that it too may function as a Sec
incorporation factor, despite the lack of biochemical evidence. It
has been reported, however, that a chimeric protein comprised of
the SBP2 SID and the SBP2L RBD had some Sec incorporation
activity, suggesting that the SBP2L RBD is capable of participating
in Sec incorporation [17]. Based on our knowledge of SBP2 it is
reasonable to predict that SBP2L function requires a stable SECIS
dependent SID-RBD interaction. Indeed, despite our conclusion
that SBP2L does not participate directly in Sec incorporation, it is
possible that it does so in a highly regulated fashion. For example,
it may be that in order for SBP2L-dependent Sec incorporation to
occur, the protein undergoes activation, possibly phosphorylation
by a signaling cascade, that would permit the SID and RBD to
stably interact. Querying the Phosphosite database [27] revealed
that phospho-SBP2L has been detected by mass spectrometry in
several high throughput studies and one modification, phospho-
Y818, is immediately downstream of the L7Ae RNA binding motif
and could be involved in regulating activity. Additionally,
microarray data from the human gene atlas [22], available at
BioGPS [23], suggests that SBP2L expression is enriched in the
central nervous system (CNS) and thyroid while SBP2 expression
is enriched in testis, thyroid, and immune cells. This difference in
tissue distribution could point toward SBP2L as a specialized Sec
incorporation factor in the CNS while SBP2 acts a generalized Sec
incorporation factor.
Conclusions
Our results highlight fundamental differences between SBP2
and SBP2L, particularly the lack of stable SBP2L SID-RBD
interactions. Additionally, the differential SECIS binding of SBP2
and SBP2L could set the stage for using these proteins and RNA
ligands as new models for understanding how RNA binding
proteins recognize their targets. Implicating SBP2L as a post-
transcriptional regulator of selenoprotein expression is a critical
first step toward deciphering SBP2L function.
Materials and Methods
Constructs
The CT-SBP2L clone in pCR3.1 used for producing in vitro
translated protein has been described previously [12] as served as a
template for subcloning the CT-SBP2L coding into pTrcHis and
for generating the CT-SBP2L deletion mutants by site-directed
mutagenesis. The CT-SBP2L coding region was PCR amplified
without its stop codon and TOPO-TA cloned into pcDNA3.1
(Invitrogen) to generate C-terminally 6xHis-V5 tagged constructs
for transfection. A full-length human SBP2L clone (BC033001)
was obtained from ATCC and the coding region was TOPO-TA
cloned into pcDNA3.1 (Invitrogen). Sequence analysis revealed
that the original ATCC clone had a mutation that generated an
L756F substitution which was corrected by site-directed muta-
genesis. The G721R SBP2L mutant was obtained by site-directed
mutagenesis. Constructs for the SBP2L SID and RBD were
obtained by PCR amplifying coding regions corresponding to
residues 467–647 and residues 648–1101 and TOPO-TA cloning
the PCR product into pTrcHis. His-FLAG tagged SBP2L RBD
was obtained by site-directed mutagenesis to convert the Xpress
tag in pTrcHis to FLAG.
The predicted amino acid sequence of Capitella SBP2L was
previously reported [17] and the sequence was refined by using
ESTs EY604926.1, EY608589.1, and EY608588.1. Protein
sequence conflicts between EY608589.1 and EY608588.1 were
resolved by consulting Capitella genomic DNA sequence. After
refinement the region encoding CT-SBP2L was synthesized with a
Pac I site 39 of the stop codon and optimization for mammalian
codon usage and cloned into pUC57 by GeneWiz (South
Plainfield, NJ). Capitella CT-SBP2L was then subcloned into the
Kpn I/Pac I sites of a luciferase construct in pcDNA3.1. A full-
length human SBP2 clone (BC036109) was obtained from ATCC
and the coding region was PCR amplified and TOPO-TA cloned
into pcDNA3.1. The coding region for human CT-SBP2 (a.a.
408–854) was PCR amplified from the full-length clone and
TOPO-TA cloned into pcDNA3.1 or pTrcHis. SBP2 SID and
RBD constructs were described previously [14]. Empty pcDNA3.1
was obtained by performing a mock TOPO-TA cloning reaction
and PCR screening clones with vector primers. Wild-type and core
deleted rat GPX4 SECIS elements have been described previously
[7]. The AAA [ TTT mutant was generated by site directed
mutagenesis. Human SECIS elements were PCR amplified with
Pac I/Not I linkers from oligo-dT primed cDNA from PC3 and
RWPE cells, HeLa cell genomic DNA (a gift from the Dougherty
lab), and synthetic oligonucleotide ultramers (Integrated DNA
Technologies) and TOPO-TA cloned into pcDNA3.1. The
luciferase reporter with a UGA codon at position 258 and rat
GPX4 SECIS has been previously described [28]. The Capitella
SelT SECIS flanked by Pac I and Not I sites was obtained by gene
synthesis (Genewiz). The human GPX4 and SelV SECIS and
Capitella SelT constructs were digested with Pac I and Not I and
the SECIS fragment was cloned into Pac I/Not I digested
luciferase reporter plasmid. Nonsilencing and SBP2L-targeting
Figure 8. Association of selenoprotein mRNAs with SBP2L in
mammalian cells. (A) Qualitative RT-PCR analysis of selenoprotein
mRNAs (GPX4 and TR1) and b-actin mRNA extracted from pre-immune
(PI) and immune (Imm) immunoprecipitations (IP) of SBP2L from
U87MG cytoplasmic extracts. (B) Qualitative RT-PCR analysis of
selenoprotein mRNAs (GPX1 and GPX4) and b-actin mRNA extracted
from pre-immune (PI) and immune (Imm) immunoprecipitations (IP) of
SBP2 and SBP2L from PC3 cytoplasmic extracts. RT, reverse transcrip-
tase.
doi:10.1371/journal.pone.0035581.g008
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constructs were confirmed by automated DNA sequencing.
Recombinant proteins
All assays in this report using recombinant proteins utilized N-
terminally 6xHis-Xpress tagged protein unless otherwise noted. All
recombinant proteins were expressed and purified from in E. coli
BL21 as described elsewhere [14,29]. 6xHis-FLAG tagged SBP2L
RBD was purified by nickel affinity chromatography as described
for the 6xHis-Xpress tagged proteins. After purification proteins
were dialyzed into 16 PBS+10% glycerol. Following dialysis
proteins were centrifuged at full speed at 4uC to pellet insoluble
material and then DTT was added to a final concentration of
2 mM.
In Vitro transcription and translation
CT-SBP2L and CT-SBP2 expression plasmids (pCDNA3.1)
were linearized with Xho I and used as templates to transcribe
capped mRNAs with the T7 mMessage/mMachine kit (Ambion)
according to the manufacturer’s protocol. Luciferase reporter
plasmids bearing the rat GPX4, human GPX4, human SelV, and
Capitella SelT SECIS elements were linearized with Xho I or Not I.
Messenger RNAs were extracted with phenol:chloroform:isoamyl
alcohol (25:24:1), purified on P30 gel filtration spin columns
(BioRad), and quantitated by UV spectrophotometry.
CT-SBP2 and CT-SBP2L in vitro transcribed mRNAs were
translated at a final concentration of 20 ng/mL in nuclease treated
rabbit reticulocyte lysate (Promega) in the presence of [
35S]-Met
according to the manufacturer’s protocol. Mock reactions were
supplemented with water instead of mRNA. Translation reactions
were incubated at 30uC for 1 hour and 2 mL were fractionated by
SDS-PAGE and visualized by phosphorimaging to confirm
protein synthesis. In vitro translated proteins were quantitated
by densitometry using
35S Met standards and assuming an
endogenous Met concentration of 5 mM in rabbit reticulocyte
lysate.
Sec incorporation assay
Selenocysteine incorporation was monitored by translating
50 ng luciferase reporter mRNA in nuclease treated rabbit
reticulocyte lysate supplemented with the indicated amounts of
recombinant protein or 2 mLo f[
35S]-Met labeled in vitro translated
protein. Final reaction volumes were 12.5 mL and were incubated
for 1 hour at 30uC. [
35S]-Met labeled reactions were analyzed for
Sec incorporation by resolving 2 mL by SDS-PAGE and
visualizing the translation products by phosphorimaging. The
remainder of the reaction was stopped by addition of 50 mL1 6
PBS and luciferase activity was measured with the firefly luciferase
assay kit (Promega).
SECIS probes and EMSA
SECIS containing plasmids were linearized with Hind III (rat
GPX4 SECIS) or Not I (all human SECIS elements) and
transcribed with T7 RNA polymerase in the presence of [
32P]-a-
UTP as described elsewhere [7]. Reactions (20 mL) containing
20 fmol SECIS RNA probe and the indicated amounts of
recombinant protein in PBSDG (16 PBS, 10% glycerol, 2 mM
DTT) were carried out in 16 PBS supplemented with 250 mg
yeast tRNA (Sigma), 10 mM DTT, and 5 mg soybean trypsin
inhibitor (Sigma) and incubated at 37uC for 30 min. Reactions
containing the GPX6 SECIS element were also supplemented
with 1 U/mL RNasin (Promega) because this SECIS was not
stable in the absence of RNase inhibitor. After incubation,
reactions were resolved on 4% nondenaturing polyacrylamide
gels. The apparent dissociation constants were determined by
generating a binding curve of the percentage of bound SECIS
RNA and calculating the protein concentration at which 50% of
the RNA was bound.
UV cross-linking
Recombinant CT-SBP2 and CT-SBP2L were incubated with
20 fmol [
32P]-a-UTP labeled SelV SECIS element as described
for EMSAs. Following incubation, complexes were UV irradiated
at 254 nm for 10 min and subsequently treated with 20 mg RNase
A for 15 min at 37uC. Samples were resolved by 10% SDS-PAGE,
and visualized by phosphorimaging.
Domains in trans co-immunoprecipitation assay
40 pmol of SBP2 or SBP2L 6xHis-Xpress SID was incubated
with equimolar amounts of FLAG-SBP2 RBD or 6xHis-FLAG
SBP2L RBD and unlabeled in vitro transcribed SECIS elements as
indicated in Figure 7 and Figure S2. SECIS elements were
transcribed with the T7 Ribomax kit (Promega) using Hind III (rat
GPX4) or Not I (human GPX4 and SelV) linearized plasmids as
template. Complexes were formed in a final volume of 70 mL
PBSDG and incubated at 30uC for 10 min. Reactions were then
brought to a final volume of 200 mL with 16 PBS+1 mM DTT
and 40 mL of 50% M2 a-FLAG agarose (Sigma) in the same buffer
and rotated for 1 hour at 4uC. Complexes were pelleted at 20006
g for 1 minute at 4uC and 50% of the supernatant was saved for
RNA extraction with TrizolLS (Invitrogen). A separate aliquot of
supernatant was saved for western blot analysis. Pellets were
washed 461 mL with 16 PBS+0.5% Tween-20. Portions
equivalent to 50% of the pellet fraction and 7.5% of the
supernatant were resolved by SDS-PAGE and analyzed by
western blotting against SBP2 or SBP2L.
SBP2L antibody
Polyclonal anti-SBP2L antibody was raised against recombinant
6xHis-Xpress CT-SBP2L in chickens (Pocono Rabbit Farm and
Laboratory). Antibodies were purified from egg yolks by
resuspending and stirring egg yolks with 10 volumes of water at
4uC and allowing the suspension to settle overnight. The soluble
fraction was centrifuged for 10 min at 10,0006 g and 4uC.
Ammonium sulfate was added to the supernatant to a final
concentration of 50% (291 g/L), mixed for 30 min at 4uC, and
centrifuged for 10 min at 10,0006 g and 4uC. Pellets were
resuspended in 3–5 mL of 16PBS and dialyzed against 3 changes
of 1L 16PBS at 4uC.
Cell culture and transfection
All cell lines were maintained at 37uC with a humidified 5%
CO2 atmosphere. HEK293 cells were cultured in DMEM+10%
newborn calf serum. U87MG cells were cultured in MEM+10%
FBS and PC3 cells in RPMI-1640+10% FBS. HEK293 cells stably
transfected with pGIPz expressing shRNAs targeting SBP2L were
selected with 2 mg/mL puromycin. Transient transfections were
performed in HEK293 cells using FuGene6 (Roche) according to
the manufacturer’s protocol. Cells were seeded 24 hours prior to
transfection at a density of 4610
5 per well in a 6 well plate and
harvested 48 hours post-transfection.
75Se labeling
Eighteen to twenty-four hours prior to harvesting, cells were
changed into medium containing
75Se (59.2 mCi/nmol) as 100 nM
Na2SeO3. Cells were washed twice with cold PBS and lysed in
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40, 0.5 sodium deoxycholate, 0.1% SDS) containing 0.5 mM
PMSF. Extracts were cleared by centrifugation at 17,0006 g,
10 min, 4uC and protein concentration was determined by
Bradford assay. Equal amounts of protein were fractionated by
15% SDS-PAGE and visualized by phosphorImaging or 10%
SDS-PAGE for western blot analysis
Immunoprecipitation and RT-PCR
U87MG cells: Twelve 100 mm dishes were cultured for 4 days,
trypsinized, and washed two times in 10 mL cold 16 PBS. The
cell pellet was resuspended in 2 mL IP buffer (20 mM Tris-HCl
pH 7.5, 150 mM NaCl, 1.5 mM MgCl2, 1 mM EGTA, 1%
Triton X-100, 0.5 mM PMSF) and rotated at 4uC for 10 min.
Extracts were cleared by centrifugation at 17,0006g, 10 min, at
4uC. RNA was extracted from 100 mL of cleared extract with
TrizolLS for input. The remaining extract was split evenly and
supplemented with 40 mL of 50% anti-IgY agarose and pre-
immune or a-SBP2L IgY. Complexes were immunoprecipitated
overnight with rotation at 4uC then washed 3 times with 1 mL of
IP buffer. On the final wash, 50% of each sample was transferred
to a fresh tube. Proteins were eluted and submitted for MudPIT
analysis by the Rutgers University mass spectrometry facility. The
other set of samples was DNase treated prior to RNA extraction
with TrizolLS. Extracted RNA (input and IP) was resuspended in
10 mL and quantitated with a NanoDrop 2000 spectrophotom-
eter (ThermoScientific). PC3 cells: Two 100 mm dishes were
supplemented with 50 nM Na2SeO3 and cultured for three days
and harvested at ,80% confluence. Cells were washed 2 times
with 5 mL of ice-cold PBS and lysed by scraping in 1 mL of IP
buffer followed by rotation for 10 min at 4uC. This extract was
cleared by centrifugation at 17,0006 g, 10 min, 4uC. Cleared
extracts were aliquoted (200 mL/tube) and supplemented with
40 mL of a 50% slurry of protein A agarose or anti-IgY agarose
and the appropriate antibody for SBP2 and SBP2L immunopre-
cipitation, respectively. Samples were processed as described for
U87MG cells but mass spectrometric analysis was omitted. For
RT-PCR, oligo-dT primed cDNAs were synthesized with
SuperScriptIII reverse transcriptase (Invitrogen) according to
the manufacturer’s protocol using 100 ng input RNA or 10 ng
immunoprecipitated RNA as template. One mLo fc D N Aw a s
used as template for PCR amplification of the indicated genes for
30 cycles.
Supporting Information
Figure S1 Capitella CT-SBP2L. Amino acid sequence of
Capitella CT-SBP2L used in Figure 1. Black arrows correspond to
ESTs. Asterisk represents the stop codon in the EST.
(EPS)
Figure S2 The SelV SECIS does not promote stable
SBP2L domain association. (A) 6xHis-Xpress SBP2L SID was
incubated with 6xHis-FLAG SBP2L was incubated with no
SECIS (2), rat (r) or human (h) GPX4 SECIS, or SelV SECIS and
complexes were immunoprecipitated (IP) with a-FLAG agarose.
Pellet fractions were analyzed by western blot (WB) for SBP2L. (B)
Same as in panel A but with 6xHis-Xpress SBP2 SID and FLAG
SBP2 RBD. (C) Stained agarose gel of RNA extracted from the
supernatants of A and B.
(EPS)
Figure S3 Deleting the conserved inter-domain linker
and C-terminal extension do not activate CT-SBP2L. (A)
SDS-PAGE gel of in vitro translated [
35S]-Met labeled input
proteins. (B) Luciferase activity obtained from in vitro translation of
the diagrammed reporter mRNA in the presence of the input
proteins from panel A.
(EPS)
Figure S4 Validation of SBP2L antibody for immuno-
precipitation. SBP2L was immunoprecipitated from U87MG
cell extracts and detected by western blot.
(EPS)
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